RecruitingNCT06644742

PKP2-ACM Natural History Study

The Natural History of Arrhythmogenic Cardiomyopathy With Pathogenic Plakophilin-2 Variants (PKP2-ACM): An Observational Cohort Study

Sponsor

Rocket Pharmaceuticals Inc.

Enrollment

36 participants

Start Date

Mar 1, 2026

Study Type

OBSERVATIONAL

Conditions

Genetic diseases Cardiomyopathies Cardiovascular Diseases Heart Diseases

Summary

The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cardiomyopathies, cardiovascular diseases, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.